Skip to content

Zoetis ZTS Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Merck & Co. logo
Merck & Co.MRK
Idexx Laboratories logo
Idexx LaboratoriesIDXX
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
Tractor Supply Company logo
Tractor Supply CompanyTSCO
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation

See full
Market cap$30.13B-54.8%
Enterprise value$38.17B-47.3%
P/E11.4×-14.4×
P/S3.2×-4.0×

Profitability

See full
Gross margin71.8%+0.8pp
Net margin27.8%+0.9pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67%+15.8pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Where this comes from

Reported directly by Zoetis in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Zoetis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zoetis's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zoetis's common stock, shares authorized (in shares)?
Zoetis (ZTS) reported common stock, shares authorized (in shares) of $6B in Q1 2026.
How has Zoetis's common stock, shares authorized (in shares) changed year-over-year?
Zoetis's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $6B to $6B.
What is the long-term trend for Zoetis's common stock, shares authorized (in shares)?
Over 3 years (2020 to 2025), Zoetis's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $6B to $6B.